These data demonstrate that PALB2 or BARD1 loss is sufficient to increase sensitivity to PARP inhibition across prostate cancer cell line models and suggests that PALB2 or BARD1 loss in prostate tumors may be associated with clinically relevant PARP inhibitor sensitivity. Here, PALB2 is linked to prostate cancer.